Table. Eligible cases lost to enrollment in a hypothetical trial of ribavirin during the first outbreak of SARS in Toronto.
Date from outbreak recognition to date of enrollment of first patient (days) | Number of cases lost to enrollment (%) |
---|---|
March 13–16 (3) |
6/249 (2) |
March 13–20 (7) |
37/249 (15) |
March 13–23 (10) |
62/249 (25) |
March 13–28 (15)a |
114/249 (46) |
March 13–31 (18)b | 149/249 (60) |
aApproval from first local ethics review board bApproval from Health Canada